Wang et al. [26] found that ropivacaine could interact with ITGB1 protein and inhibit the expression of ITGB1 protein in colon cancer cells, thereby affecting its downstream Akt and ERK signaling pathways. Here, AKT1 is linked to colonic neoplasm.